for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Idorsia Ltd

IDIA.S

Latest Trade

25.76CHF

Change

0.36(+1.42%)

Volume

349,498

Today's Range

25.06

 - 

25.84

52 Week Range

15.20

 - 

28.00

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
25.40
Open
25.50
Volume
349,498
3M AVG Volume
7.36
Today's High
25.84
Today's Low
25.06
52 Week High
28.00
52 Week Low
15.20
Shares Out (MIL)
131.23
Market Cap (MIL)
3,333.37
Forward P/E
-6.92
Dividend (Yield %)
--

Latest Developments

More

Idorsia In Partnership With Antares To Develop Drug-Device Product For Selatogrel

Idorsia 9-Month US GAAP Operating Loss CHF 355 Million

Idorsia Says Janssen Reports Positive Top-Line Phase 3 Results For Ponesimod

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Idorsia Ltd

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Industry

Biotechnology & Drugs

Contact Info

Hegenheimermattweg 91

https://www.idorsia.com

Executive Leadership

Jean-Pierre Garnier

Non-Executive Independent Chairman of the Board

Jean-Paul Clozel

Chief Executive Officer, Delegate of the Board, Member of the Executive Board

Andre C. Muller

Chief Financial Officer, Executive Vice President, Member of the Executive Board

Martine Clozel

Executive Vice President, Chief Scientific Officer, Member of the Executive Board

Simon Jose

Executive Vice President, Chief Commercial Officer, Member of the Executive Board

Key Stats

3.00 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2017

0.2K

2018

0.1K

2019(E)

0.0K
EPS (CHF)

2017

0.030

2018

-3.100

2019(E)

-3.805
Price To Earnings (TTM)
--
Price To Sales (TTM)
54.99
Price To Book (MRQ)
10.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
176.30
LT Debt To Equity (MRQ)
176.30
Return on Investment (TTM)
-37.36
Return on Equity (TTM)
-34.75

Latest News

Latest News

Idorsia's Clozel says recruitment delay won't dent Fabry drug prospects

Fledgling Swiss biotech Idorsia has suffered delays in recruiting patients for a key trial of its experimental lucerastat drug but that will not damage its commercial prospects, founder Jean-Paul Clozel told Reuters on Tuesday.

BRIEF-Idorsia 9-Month US GAAP Operating Loss CHF 355 Million

* US GAAP REVENUE OF CHF 20 MILLION IN FIRST NINE MONTHS OF 2019 AS WELL AS 2018

BRIEF-Idorsia Says Janssen Reports Positive Top-Line Phase 3 Results For Ponesimod

* JANSSEN REPORTS POSITIVE TOP-LINE PHASE 3 RESULTS FOR PONESIMOD IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS

BRIEF-Idorsia H1 US GAAP Net Loss At CHF 232 Mln

* UNCHANGED GUIDANCE FOR 2019: US GAAP OPERATING EXPENSES OF AROUND CHF 570 MILLION

UPDATE 1-Idorsia confirms 2019 spending plan as clinical trials "on track"

Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.

BRIEF-Idorsia Q1 US GAAP Net Loss Widens To CHF 106 Mln

* IDORSIA ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2019

Idorsia 'cuts Actelion umbilical cord', says cash pile suffices

Idorsia founder and CEO Jean-Paul Clozel said his biotech group has the resources to assess trial data and decide what to do with assets, as spending on projects led to a 386 million Swiss franc ($385 million) loss in 2018.

BRIEF-Idorsia: First Patient Recruited Into React - Phase 3 Registration Study With Clazosentan

* ANNOUNCES FIRST PATIENT RECRUITED INTO REACT - PHASE 3 REGISTRATION STUDY WITH CLAZOSENTAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Idorsia Starts Multiple-Dose Efficacy And Safety Study With Cenerimod For Treatment Of Systemic Lupus Erythematosus

* IDORSIA INITIATES A MULTIPLE-DOSE EFFICACY AND SAFETY STUDY WITH CENERIMOD FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Idorsia's Selatogrel Phase 2 Clinical Studies Meet Their Objective

* IDORSIA'S P2Y12 RECEPTOR ANTAGONIST - SELATOGREL - PHASE 2 CLINICAL STUDIES MEET THEIR OBJECTIVE

BRIEF-Idorsia Maintains Collaboration Agreement With Reveragen

* FOLLOWING RECEIPT OF CLINICAL STUDY REPORT FOR PHASE 2A STUDY WITH VAMOROLONE, WILL PAY REVERAGEN USD 15 MILLION TO MAINTAIN AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Idorsia Says Representative Of Former Axovan Shareholders Filed Complaint Against Actelion

* SAYS REPRESENTATIVE OF FORMER AXOVAN SHAREHOLDERS CLAIMS DEMERGER OF ACTELION AND IDORSIA WOULD TRIGGER ACCELERATION OF ALL OUTSTANDING MILESTONE PAYMENTS FOR CLAZOSENTAN

BRIEF-Idorsia 9Mth US GAAP Net Loss Of CHF 278 Mln

* US GAAP OPERATING RESULTS IN 9M 2018: LOSS OF CHF 271 MILLION

BRIEF-Idorsia H1 US GAAP Net Loss At CHF 159 Mln

* US GAAP OPERATING RESULTS IN HY 2018: LOSS OF CHF 155 MILLION

UPDATE 1-Idorsia CEO accelerates fundraising with 505 mln Sfr deal

Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

Idorsia raises 505 mln Sfr from shares, bonds to fund pipeline

Swiss drugmaker Idorsia's Chief Executive Jean-Paul Clozel on Wednesday accelerated fundraising for his drug pipeline, reaping around 505 million Swiss francs ($509 million) by selling new shares and convertible bonds.

BRIEF-Idorsia Launches Offering Of New Shares And Convertible Bonds

* IDORSIA LAUNCHES THE OFFERING OF NEW SHARES IN COMBINATION WITH THE OFFERING OF CONVERTIBLE BONDS TO FUND THE DEVELOPMENT OF ITS ADVANCING PIPELINE

After split from Actelion, Idorsia CEO plans to raise more cash in 2019

Swiss biotech Idorsia <IDIA.S>, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson <JNJ.N>, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters.

BRIEF-Idorsia Initiates Phase 3 Registration Program With Nemorexant For Treatment Of Insomnia

* INITIATES A PHASE 3 REGISTRATION PROGRAM WITH NEMOREXANT (ACT-541468) FOR TREATMENT OF INSOMNIA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease

* IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up